Mesa Laboratories CFO John Sakys Sells Shares
John Sakys, CFO of Mesa Laboratories, sold 2,827 shares on June 22.
Key Points
- John Sakys, CFO of Mesa Laboratories, sold 2,827 shares on June 22 for $253,016.50, with the stock priced at $89.50.
- Mesa Laboratories, trading at $93.23 on Tuesday, has a market cap of $515 million and a P/E ratio of 77.05.
- Long Path Partners increased its holdings in Mesa Laboratories by 178,360 shares, while Vanguard opened a new position.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
John Sakys, the Chief Financial Officer of Mesa Laboratories, Inc. (NasdaqGS: MLAB), sold 2,827 shares of the company on June 22, 2026. The shares were sold at an average price of $89.50, totaling about $253,016.50. This transaction was not part of a pre-planned 10b5-1 trading plan.
Insider Buying and Selling at Mesa Laboratories, Inc.
Alongside Sakys, Brian David Archbold, Senior Vice President of Operations, also made notable trades. On June 22, Archbold sold 2,516 shares at the same price of $89.50. Earlier, on June 18, both Sakys and Archbold were involved in buying activities, with Sakys purchasing 2,282 shares at $95.10 and selling 1,036 shares on the same day without a stated price.
Other Institutional Activity in Mesa Laboratories
Long Path Partners LP significantly increased its stake in Mesa Laboratories, adding 178,360 shares to hold a total of 405,583 shares, valued at approximately $35.86 million, marking a 78.5% increase. Meanwhile, BlackRock, Inc. slightly reduced its position by 4,815 shares, ending with 393,851 shares worth about $34.82 million, a 1.2% decrease. Boston Partners boosted its holdings by 55,335 shares, reaching 268,711 shares valued at $23.76 million, reflecting a 25.9% increase. Select Equity Group, L.P. also increased its stake by 29,450 shares to 235,885 shares, valued at $20.86 million, a 14.3% rise. Vanguard Capital Management LLC opened a new position with 232,643 shares worth about $20.57 million.
Mesa Laboratories, Inc. Stock Down 28.7%
Shares of Mesa Laboratories traded near $93.23 on Tuesday. The company has a market capitalization of approximately $515 million and a P/E ratio of 77.05. Its forward P/E ratio is notably lower at 7.60, suggesting anticipated earnings growth. The stock's beta is 0.927, indicating it is less volatile than the broader market. Over the past 52 weeks, Mesa Laboratories' stock has ranged from a low of $55.45 to a high of $113.99, with a 50-day moving average of $101.99 and a 200-day moving average of $84.97.
$MLAB stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Mesa Laboratories reported revenue of $249.13 million, reflecting a growth rate of 2.6%. The company's earnings per share stood at $1.21, with a net margin of 2.7% and a return on equity of 3.9%. Investors can look forward to the next earnings report on August 5, 2026.
Dividend
The company offers an annual dividend rate of $0.64, yielding 0.67%. Its dividend payout ratio is 52.9%, indicating a moderate portion of earnings is returned to shareholders. The ex-dividend date was not specified.
Analysts Set New Price Targets
On February 4, 2026, Wells Fargo maintained its hold rating on Mesa Laboratories with a price target of $94.00. The analyst consensus features a mean target price of $112.00, with two analysts providing opinions. The high target is $130.00, and the low target is $94.00.
About Mesa Laboratories, Inc.
Mesa Laboratories, Inc. is a technology company specializing in the development, design, manufacture, and service of life sciences tools and quality control products. Operating primarily in the scientific and technical instruments industry, it serves the pharmaceutical, medical device, and healthcare industries with sterilization and disinfection control products. Headquartered in Lakewood, Colorado, the company is led by CEO Dr. Siddhartha Chandrakant Kadia and employs about 717 people.
Bottom Line
Insider trading activities at Mesa Laboratories, like those by CFO John Sakys, are always of interest to investors monitoring executive sentiment. The company's recent institutional activity shows varied interest from major funds, reflecting confidence in its strategic direction. As always, these insights are based on historical data and may not reflect current conditions.
Get Mesa Laboratories, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MLAB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.